Quinazoline Derivative Inhibits KRAS G12C Mutation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current KRAS G12C mutation inhibitors face challenges such as suboptimal inhibitory activity, rapid development of drug-resistant mutations, and poor metabolic stability, limiting their effectiveness in treating cancers with this mutation.
Innovation Solution
A compound of formula (II) or its pharmaceutically acceptable salt/stereoisomer, specifically designed with a substituted quinazoline derivative structure, which effectively inhibits KRAS G12C mutation, prevents drug-resistant mutations, and enhances metabolic stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prior art KRAS G12C inhibitors (AMG510, MRTX849) are used, then some inhibitory activity is achieved, but the inhibitory activity is suboptimal and drug-resistant mutations develop rapidly
Solution Approach 1:
The patent modifies the chemical structure parameters of KRAS G12C inhibitors by introducing specific substituents at defined positions (R1-R10, L, ring A) to optimize binding affinity and selectivity. This structural parameter optimization enables the compound to maintain potent inhibition of KRAS G12C while preventing adaptation through mutation, directly resolving the contradiction between achieving reliable inhibition and preventing drug resistance.
Solution Approach 2:
The invention creates a composite molecular structure combining a quinazoline core with diverse substituent groups (aromatic, heterocyclic, aliphatic chains) that work synergistically. This composite structure provides multiple interaction points with the KRAS G12C target, enhancing binding reliability while reducing the likelihood of drug-resistant mutations developing, as the multi-point binding makes it harder for the target to adapt.
2Reliability
If prior art KRAS G12C inhibitors are used, then some therapeutic effect is achieved, but metabolic stability is poor
Solution Approach 1:
The patent optimizes metabolic stability by carefully selecting and positioning substituent groups that resist metabolic degradation. Specific substituents (halogens, aromatic groups, cyclic structures) are placed at strategic positions to protect against cytochrome P450 metabolism and other metabolic pathways. This allows the compound to maintain both therapeutic effect and improved metabolic stability simultaneously.
3Ease of operation
If existing KRAS G12C inhibitors are developed, then drug action is achieved, but the compounds cannot prevent drug-resistant mutations
Solution Approach 1:
The patent employs preliminary anti-action by designing a compound structure that proactively prevents drug-resistant mutations before they can develop. The optimized quinazoline derivative with specific substituents creates a binding mode that eliminates the structural flexibility needed for resistance mutations, thereby maintaining effective drug action while preemptively blocking the development of drug resistance.
Data Source
AI summary
Provided are a quinazoline derivative of formula (II) and a preparation method therefor, the quinazoline derivative being used as a KRAS G12C mutation inhibitor. The KRAS G12C mutation inhibitor can more efficiently inhibit KRAS G12C mutation, prevents drug-resistant mutation, and has good metabolic stability.